Go to content
UR Home

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

URN to cite this document:
urn:nbn:de:bvb:355-epub-415481
Ribback, Silvia ; Sailer, V. ; Böhning, E. ; Utpatel, Kirsten ; Evert, Matthias ; ,
[img]
Preview
License: Creative Commons Attribution 4.0
PDF - Published Version
(11MB)
Date of publication of this fulltext: 11 Feb 2020 11:17


Abstract

Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression of pre-neoplastic liver lesions to HCC. In short-and long-term experiments, administration of ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons